UMB Bank is suing Bristol Myers Squibb, claiming the pharmaceutical company slow-walked approval a drug for treating cancer in order to avoid paying more under terms of a pervious acquisition.
The bank brought the action as trustee seeing that Bristol Myers adhered to terms of a part of the pharma company’s purchase of Celgene Corp. in late 2019, Biopharma Drive reports. The term called for Bristol Myers to pay $9 a share — $6.4 billion in total — more to Celgene stockholders if three drugs…UMB sues Bristol Myers Squibb over slowed approval of cancer treatment Breyanzi
UMB Bank is suing Bristol Myers Squibb, claiming the pharmaceutical company slow-walked approval a drug for treating cancer in order to avoid paying more under terms of a pervious acquisition.
The bank brought the action as trustee seeing that Bristol Myers adhered to terms of a part of the pharma company’s purchase of Celgene Corp. in late 2019, Biopharma Drive reports. The term called for Bristol Myers to pay $9 a share — $6.4 billion in total — more to Celgene stockholders if three drugs…